Skip to main content

Immunotherapy

Progression of Metastatic, PD-L1–Positive, Ampullary Carcinoma with a Treatment Holiday from Off-Label Use of Pembrolizumab Therapy

Hayley Heers, PharmD, BCPS; Amin Seyedkazemi, DO; Natalee Tanner, PharmD, BCOP; Madappa Kundranda, MD, PhD, FACP

The Intersection of Immunotherapy and Targeted Therapy in Lung Cancer

Meg Barbor, MPH

Rapid Onset of Severe Transaminitis in a Patient with Non–Small-Cell Lung Cancer After First Dose of Nivolumab 480 mg

Matthew Stankowicz, PharmD, BS; Megan Banaszynski, PharmD, BCOP; Russell Crawford, RPh, BCOP

Meeting Highlights

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome

Meeting Highlights

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer

CAR T-Cell Therapy Targeting Solid Tumors

Meeting Highlights

Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy

Phoebe Starr, Medical Writer

Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Page 3 of 4
Results 21 - 30 of 39